Current Status of Molecular Diagnosis of Hereditary Hemolytic Anemia in Korea
10.3346/jkms.2024.39.e162
- Author:
Hee Won CHUEH
1
;
Ye Jee SHIM
;
Hye Lim JUNG
;
Namhee KIM
;
Sang Mee HWANG
;
Myungshin KIM
;
Hyoung Soo CHOI
;
Author Information
1. Department of Pediatrics, Inje University Haeundae Paik Hospital, Busan, Korea
- Publication Type:Review Article
- From:Journal of Korean Medical Science
2024;39(18):e162-
- CountryRepublic of Korea
- Language:EN
-
Abstract:
Hereditary hemolytic anemia (HHA) is considered a group of rare hematological diseases in Korea, primarily because of its unique ethnic characteristics and diagnostic challenges.Recently, the prevalence of HHA has increased in Korea, reflecting the increasing number of international marriages and increased awareness of the disease. In particular, the diagnosis of red blood cell (RBC) enzymopathy experienced a resurgence, given the advances in diagnostic techniques. In 2007, the RBC Disorder Working Party of the Korean Society of Hematology developed the Korean Standard Operating Procedure for the Diagnosis of Hereditary Hemolytic Anemia, which has been continuously updated since then. The latest Korean clinical practice guidelines for diagnosing HHA recommends performing nextgeneration sequencing as a preliminary step before analyzing RBC membrane proteins and enzymes. Recent breakthroughs in molecular genetic testing methods, particularly nextgeneration sequencing, are proving critical in identifying and providing insight into cases of HHA with previously unknown diagnoses. These innovative molecular genetic testing methods have now become important tools for the management and care planning of patients with HHA. This review aims to provide a comprehensive overview of recent advances in molecular genetic testing for the diagnosis of HHA, with particular emphasis on the Korean context.
